Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity – Nasdaq

<![CDATA[
/**/
]]>
<![CDATA[
/**/
]]>

DALLAS, April 17, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.¬† KALY owns and operates a patented cannabis extraction process. Following four years of research and development, the company recently executed a strategy to bring the resulting intellectual property (IP) into a public company as part of a plan to capitalize its next stage of development.¬† KALY is that public company platform.¬† In conjunction with that plan, the company has recently disclosed four of its leading research and development initiatives targeting four specific health issues:¬†

  • Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
  • Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
  • Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
  • Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
  • The presentation below and incorporated into the company’s website offers further detail on the company’s progress to date and plans moving forward to commercialize cannabis therapies.

    Patented Cannabis Extracts Targeting $170 Million Pharmaceutical Treatments

    In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB).  NCMB is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.  In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.  KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds.  KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.

    $170 Million Cannabis Therapeutics Market Opportunity

  • Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
  • Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
  • Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
  • Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
  • Cannabis Research Methodology

    KALY, through its subsidiary NCMB focuses on the use of specific cannabis extracts alone, and also along with using a proprietary process which combines molecules of already proven therapeutic utility to combat a variety of clinical disorders.  In recognition of the need to standardize candidate products and to determine mechanisms for action with scientific credibility, KALY has established collaborations with other companies and with universities to enhance understanding and provide scientific support to the introduction of novel cannabis extract formulations for the consumer marketplace.

    KALY has already published its COPD research and initiated a second stage of research and development.¬† Research reports on the first phase of development for KALY’s cannabis compounds for Type 2 Diabetes, Cancer Pain Management and Epilepsy are expected to be published later this year.

    To accelerate development, KALY is developing key partners with an emphasis on establishing joint ventures with existing biopharmaceutical companies.  The company has a $3.5 million development plan for its next stage of development and management is working diligently to fund that development plan through the capital structure of partner companies.

    Beyond The Initial Four Therapies

    Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline. KALY’s proprietary extracts have been evaluated in a genomic study where the extracts have exhibited remarkable activity in gene arrays by up or down regulating individual genes by as much as 200 fold.¬† Genes appearing especially sensitive to the introduction of KALY’s cannabis extracts were associated with inflammation, healing and cancer inhibition.¬† The results of the genomic studies have served to initiate planning for a host of additional therapies that can be developed from KALY’s proprietary cannabis extracts.

    $1 Million 2019 Revenue Target From Parallel Revenue Strategy

    KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success.¬† With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.¬† Drawing on KALY’s patented cannabis extraction expertise, Puration’s (USOTC:PURA) EVERx CBD Sports Water is already the leading CBD infused beverage for the sports nutrition market.¬† KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way.¬† Hemp4mula is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis Holdings, Inc. (USOTC:USMJ) (aka USMJ).¬† KALY has also entered into a partnership with Nouveau (USOTC:NOUV), a cannabis cultivation company, with plans to develop a proprietary cannabis cultivar that can further enhance the quality of KALY’s extracts.¬† KALY’s consumer revenue strategy offers a business line that can stand alone, but one that also provides KALY with the long-term staying power to take the necessary time to bring its cannabis extract biopharmaceutical products to market.¬† Currently, KALY management anticipates that its $1 million 2019 revenue goal for its parallel consumers market strategy is well within reach.

    To learn more about the company visit https://www.kali-extracts.com/

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

    CONTACT:

    Frederick Ferri

    ir@kali-extracts.com

    (214) 210-0459

    Source: Kali, Inc.

Source: https://www.nasdaq.com/press-release/kali-extracts-presents-cannabis-extract-biopharmaceutical-strategy-targeting-170-million-20190417-00633

« »